On February 26, 2026 RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, reported that a clinical data abstract submission by cancer experts at Moffitt Cancer Center to the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting has been accepted. The meeting will be held April 11-15, 2026, in Toronto, Ontario.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract, titled "What PET/CT Reveals After Transarterial Microperfusion for Pancreatic Cancer," was submitted by a multidisciplinary team of cancer experts, including Dr. Mustafa Al-Roubaie, an Interventional Radiologist at Moffitt Cancer Center and member of RenovoRx’s Medical Advisory Board. The abstract explores the hypothesis, based on a review of metabolic response observations, that local, targeted intra-arterial delivery of chemotherapy using RenovoRx’s patented TAMP (Trans-Arterial Micro-Perfusion) therapy platform may help address the poor vascularity commonly associated with locally advanced pancreatic cancer (LAPC). The abstract data further evaluates the potential role of metabolic imaging (FDG (fluorodeoxyglucose) PET/CT)) in evaluating therapeutic activity following targeted intra-arterial treatment in patients with refractory disease.
"Patients diagnosed with LAPC carry a difficult prognosis, partly due to a dense, hypovascular stroma that limits the efficacy of traditional systemic (intravenous) chemotherapy," said Dr. Al-Roubaie. "Regional intra-arterial therapeutic delivery, which is the core attribute of RenovoRx’s TAMP therapy platform, aims to overcome this barrier by delivering high-concentration chemotherapy directly near the tumor. We are excited to present our findings at the upcoming 2026 SIR Meeting."
Abstract Details:
Presentation Date & Time: Monday, April 13, 2026, from 4:45-5:45 PM ET
Title: What PET/CT Reveals After Transarterial Microperfusion for Pancreatic Cancer
Location: Metro Toronto Convention Centre – Toronto, Canada
Abstract Number: 2229370
About RenovoCath
Based on its FDA clearance, RenovoCath is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to select sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use ("IFU"), please see: IFU-10004-Rev.-G-Universal-IFU.pdf.
(Press release, Renovorx, FEB 26, 2026, View Source [SID1234663105])